Discovery of Ro 48-5695: A potent mixed endothelin receptor antagonist optimized from bosentan
- 1 September 1997
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 7 (17), 2223-2228
- https://doi.org/10.1016/s0960-894x(97)00400-9
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Endothelin receptors: Receptor classification, novel receptor antagonists, and potential therapeutic targetsMedicinal Research Reviews, 1996
- Up-Regulation of Endothelin-B Receptors in Atherosclerotic Human Coronary ArteriesJournal of Cardiovascular Pharmacology, 1996
- Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failureThe Lancet, 1995
- Separable Binding Sites for the Natural Agonist Endothelin-1 and the Non-Peptide Antagonist Bosentan on Human Endothelin-A ReceptorsEuropean Journal of Biochemistry, 1995
- ET A and ET B Receptors Mediate Contraction to Endothelin-1 in Renal Artery of Aging SHRHypertension, 1995
- Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonistNature, 1993
- The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivoBiochemical and Biophysical Research Communications, 1992
- Cloning and expression of a cDNA encoding an endothelin receptorNature, 1990
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988
- Synthesis of furan derivatives. LXXXIII. Kinetics of acyl azide formation of carboxylic acids with diphenyl phosphorazidate.CHEMICAL & PHARMACEUTICAL BULLETIN, 1977